Collegium Pharmaceutical, Inc. (COLL) Stock

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is led by CEO Vikram Karnani, employs 357 people, headquartered in US, publicly traded since 2015.

Collegium Pharmaceutical, Inc. (COLL) stock trades at $22.96 with a market capitalization of $747.48M. The stock is valued at a price-to-earnings (P/E) ratio of 14.47, price-to-book of 2.30, price-to-sales of 0.89. Over the past 52 weeks the stock has ranged between $21.53 and $50.79, and currently trades 54.8% below its 52-week high.

On profitability, Collegium Pharmaceutical, Inc. generates a return on equity (ROE) of 15.96%, above the typical market range of roughly 12-15%, return on capital employed of 10.25%, an operating margin of 15.96%, a net profit margin of 5.93%.

Collegium Pharmaceutical, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Collegium Pharmaceutical, Inc. reported revenue of $2.0M rising to $781.0M, a change of +38950.0% across 10 years. Compounded, revenue has grown 20.3% a year over five years, 18.9% over three, 23.8% over the last twelve months. Net profit rose to $63.0M.

Operating margin went from -5498.7% in 2016 to 24.0% in 2025, a gain of 5522.6 percentage points. The most recent net margin is 5.93%. On a trailing twelve-month basis to Jun '26, revenue is $808.0M and net profit $48.0M.

Borrowings rose from $4.0M to $941.0M, cash from operations was $329.0M in the latest year, positive in 8 of the last 10.

Return on equity has averaged 19.6% over five years, and was 20.9% in the most recent year.

The share price itself has compounded at 10.4% a year over five years, 15.7% over three, 20.7% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Collegium Pharmaceutical, Inc. (COLL) — frequently asked questions